|Podcasts|February 22, 2018

Episode 3: Pharma's Reputation

In this episode, Christen and Michelle talk to Devyn Smith, chief strategy officer and head of operations for Sigilon Therapeutics, on the topic of pharma's reputation, both in the US and Europe.

In this episode, Christen and Michelle talk to Devyn Smith, chief strategy officer and head of operations for Sigilon Therapeutics, on the topic of pharma's reputation, both in the US and Europe.

You can listen and/or download the episode on SoundCloud or directly through iTunes, GooglePlay, Stitcher, and Overcast.

 

 


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.